Sero-prevalence of Hepatitis B Virus Infection in Balochistan Province of Pakistan

Nadeem S. Sheikh, Azeem S. Sheikh1, Aqleem A. Sheikh2, Samira Yahya3, Rafi-U-Shan4, Majid Lateef5

ABSTRACT

Background/Aim: The objective was to evaluate the sero-prevalence of hepatitis B surface antigen (HBsAg) and IgM antibodies to hepatitis core antigen in Balochistan Province of Pakistan. Design of the study: A cross-sectional, population-based study. Place and time of the study: The study was conducted in Balochistan from 1st January 2004 to 31st December, 2008. The screening areas included Barkhan, Eashani, Khuzdar, Kodi Zikriani, Kohlu, Rakhni and Turbat. Materials and Methods: A total of 15,260 subjects were enrolled; 11,900 (78%) agreed to undergo screening. Fresh serum samples were tested for the presence of hepatitis B surface antigen and IgM antibodies to hepatitis B core antigen. Results: HBsAg was detected in 1166 (9.8%) while anti-HBc IgM was found in 117 (10.0%). HBsAg positivity was seen in 875 (12.7%) males and 291 (5.8%) females. The prevalence of hepatitis B in Balochistan varies from 3.3% in Khuzdar to 17.0% in Kodi Zikriani. Conclusions: It is utmost important to educate the public, to take proper measures to control the spread of infection and vaccination in order to interrupt transmission of this threatening public health problem in Balochistan province of Pakistan.

Key Words: Cirrhosis, HBsAg, hepatitis B, hepatitis, prevalence

Received 10.04.2010, Accepted 14.05.2010
How to cite this article: Sheikh NS, Sheikh AS, Sheikh AA, Yahya S, R, Lateef M. Sero-prevalence of Hepatitis B Virus infection in Balochistan province of Pakistan. Saudi J Gastroenterol 2011;17:180-4.
detected in the serum from several weeks before onset of symptoms to months after onset. HBsAg is present in serum during acute infections and persists in chronic infections. The presence of HBsAg indicates that the person is potentially infectious. The presence of HBeAg is associated with relatively high infectivity and severity of disease.

Demonstration of IgM anti-HBc in serum indicates HBV infection, current or past. IgM anti-HBc is present in high titre during acute infection and usually disappears within six months although it can persist in some cases of chronic hepatitis. This test may, therefore, reliably diagnose acute HBV infection. IgG anti-HBc generally remains detectable for a lifetime.

Acute hepatitis patients who maintain a constant serum HBsAg concentration or whose serum HBeAg persists eight to ten weeks after symptoms have resolved, are likely to become carriers and are at risk of developing chronic liver disease.

This study was conducted as a population screening for chronic hepatitis B in the interior of Balochistan to know the brunt of the disease in these areas.

MATERIALS AND METHODS
The study has been conducted as a cross-sectional, population-based screening in the interior of Balochistan between 1st January 2004 and 31st December, 2008. Keeping in view that the community data on the prevalence of HBsAg that are critical to define immunization strategies against hepatitis B virus infection are scarce, the present study has been designed. The sample size was provided by the Provincial office of the Federal Bureau of Statistics, who has the sampling frame of whole of Balochistan. Based on that sampling frame, they drew a multi-stage sample comprising 2270 households. The screening areas included the rural areas of Barkhan, Eeshani, Khuzdar, Kodi Zikriani, Kohlu, Rakhni, and Turbat. From these households, a total of 15,260 subjects were accessed for enrollment in this study, out of which 11,900 (78%) agreed to undergo screening. There was no difference in the Brink of the disease in these areas.

RESULTS
Out of the total of 11900 subjects screened, HBsAg was detected in 1166 (9.8%). These surface antigen positive subjects of viral hepatitis were further tested for anti-HBc IgM, which was found reactive in 117 (10.0%). This shows that out of the total studied subjects, 1049 (8.8%) were actually chronic HBV carriers and only 117 (10.0%) subjects were having acute HBV infection. HBsAg positivity was seen to be highest in Kodi Zikriani (17.0%) and lowest in Khuzdar (3.3%) of all the studied areas, as shown in Table 1.

The gender distribution of HBV infected subjects is shown in Table 2. A total of 6874 (57.7%) males and 5026 (42.2%) females were screened for HBV infection. HBsAg positivity was seen in 875 (12.7%) males and 291 (5.8%) females; anti-HBc IgM was positive in 76 (8.6%) males and 41 (14.0%) females highlighting an acute infection. The gender – HBsAg difference was statistically significant (P ≤ 0.000).

The age distribution of HBV infected subjects is shown in Table 3. The major bulk of HBsAg positive subjects, about 30%, consisted of subjects between 20 and 49 years of age. Comparing means shows that age – gender (P = 0.000) and age – HBsAg (P = 0.000) difference was statistically significant.

The age-specific risk factors identified in HBV infected subjects are shown in Table 4.
### Table 1: Area-specific seropositivity for HBsAg and anti-HBc IgM (n=11900)

| Area       | No. of screened subjects (%) | HBsAg positive No. (%: 95% CI) | Anti-HBc IgM positive No. (%: 95% CI) |
|------------|-----------------------------|---------------------------------|--------------------------------------|
| Barkhan    | 982 (8.2)                   | 119 (12.1: 9.4 – 14.8)          | 22 (18.5: 13.7 – 23.3)               |
| Eeshani    | 1045 (8.7)                  | 78 (7.5: 6.3 – 8.7)             | 11 (14.1: 12.4 – 15.8)              |
| Khuzdar    | 2760 (23.1)                 | 91 (3.3: 2.7 – 3.9)             | 0.00                                 |
| Kodi Zikriani | 1075 (9.0)              | 183 (17.0: 14.8 – 19.2)         | 32 (17.5: 11.9 – 23.1)              |
| Kohlu      | 3530 (29.6)                 | 535 (15.1: 13.9 – 16.3)         | 38 (7.1: 5.4 – 8.8)                 |
| Rakhni     | 898 (7.5)                   | 82 (9.1: 7.8 – 10.4)            | 0.00                                 |
| Turbat     | 1610 (13.5)                 | 78 (4.8: 3.4 – 6.2)             | 14 (18.0: 16.9 – 19.1)              |
| Total      | 11900                       | 1166 (9.8: 7.5 – 12.1)          | 117 (10.0: 8.2 – 11.8)              |

*Calculated as percentage of HBsAg positive cases

### Table 2: Distribution of seropositive subjects by gender (n=11900)

| Gender | Total screened (%) | HBsAg positive (%) | Anti-HBc IgM positive (%) |
|--------|--------------------|--------------------|---------------------------|
| Males  | 6874 (57.7)        | 875 (12.7)         | 76 (8.6)                  |
| Females| 5026 (42.2)        | 291 (5.8)          | 41 (14)                   |

*Calculated as percentage of HBsAg positive gender-specific cases

### Table 3: Age-specific seropositivity for HBsAg and anti-HBc IgM (n=11900)

| Age group (years) | No. of screened subjects (%) | HBsAg positive (%) | Anti-HBc IgM positive (%) |
|-------------------|------------------------------|--------------------|---------------------------|
|                   | Male                         | Female             | Male                      | Female                    |
| 01-09             | 1907 (16.0)                  | 53 (2.8)           | 15 (0.8)                  | 9 (17.0)                  |
| 10-19             | 1255 (10.5)                  | 93 (7.4)           | 28 (2.2)                  | 8 (8.6)                   |
| 20-29             | 1849 (15.5)                  | 224 (12.1)         | 68 (3.7)                  | 13 (5.8)                  |
| 30-39             | 2255 (19.0)                  | 277 (12.2)         | 60 (2.6)                  | 15 (5.4)                  |
| 40-49             | 2142 (18.0)                  | 151 (7.0)          | 71 (3.3)                  | 18 (12.0)                 |
| 50-59             | 1449 (12.1)                  | 77 (5.3)           | 49 (3.4)                  | 13 (16.8)                 |
| ≥ 60              | 1043 (8.7)                   | 0.00               | 0.00                      | 0.00                      |
| Total             | 11,900                       | 875 (7.3)          | 291 (2.4)                 | 76 (8.8)                  |

*Calculated as percentage of HBsAg positive gender-specific cases in each age-specific category

### Table 4: Age-specific risk factors identified in HBV infected subjects (n=1166)

| Age group (years) | Unknown (%) | Inoculation/needle use (%) | Heterosexual/extramartial (%) | IV drug use (%) | Blood transfusion (%) | Dialysis (%) | Previous surgery (%) |
|-------------------|-------------|---------------------------|-------------------------------|----------------|-----------------------|--------------|----------------------|
| 01-09             | 26 (2.2)    | 17 (1.45)                 | 00.00                         | 00.00          | 00.00                 | 6 (0.5)      | 19 (1.6)             |
| 10-19             | 29 (2.4)    | 21 (1.8)                  | 23 (2.0)                      | 5 (0.4)        | 8 (0.7)               | 5 (0.4)      | 15 (1.3)             |
| 20-29             | 68 (5.8)    | 15 (1.3)                  | 45 (3.8)                      | 42 (3.6)       | 39 (3.3)              | 9 (0.7)      | 41 (3.5)             |
| 30-39             | 62 (5.3)    | 12 (1.0)                  | 55 (4.7)                      | 34 (2.9)       | 42 (3.6)              | 17 (1.45)    | 82 (7.0)             |
| 40-49             | 41 (3.5)    | 8 (0.7)                   | 34 (2.9)                      | 27 (2.3)       | 25 (2.1)              | 12 (1.0)     | 40 (3.4)             |
| 50-59             | 28 (2.4)    | 9 (0.7)                   | 21 (1.8)                      | 00.00          | 16 (1.3)              | 10 (0.8)     | 39 (3.3)             |
| 60 and above      | 00.00       | 00.00                     | 00.00                         | 00.00          | 00.00                 | 00.00        | 00.00                |
| Total             | 254 (21.6)  | 82 (7.0)                  | 178 (15.2)                    | 108 (9.2)      | 130 (11.0)            | 59 (4.8)     | 236 (20.1)           |

### DISCUSSION

Chronic viral hepatitis is one of the major public health problems in Pakistan. HBV has been reported in Pakistan with a prevalence rate of 10% in some studies. In 2001–2002, Pakistan received a grant from the Global Alliance for Vaccines and Immunization (GAVI) that has enabled the introduction of hepatitis B vaccination in routine Expanded program on immunization (EPI). Vaccination for HBV as part of EPI was launched in a nationwide vaccination campaign in 2004. According to the statistics obtained in this study, HBV infection has been detected in 9.8% of the subjects in the areas, out of which 10.0% had the acute infection, being positive both for HBsAg and IgM anti-HBc while 8.8% were chronic carriers, being positive for HbsAg only. Majority
(≈50%) of the chronic HBV infected subjects were in the age group of 30-50 years. The carrier prevalence rates among males and females were 7.3% and 2.4%, respectively.

The prevalence of hepatitis B in the interior of Balochistan varies from as low as 3.3% in Khuzdar to as high as 17.0% in Kodi Zikrian. The situation in Barkhan, Eeshani, Kohlu and Rakhni is alarming with prevalence of 12.1%, 7.5%, 15.1% and 9.1% respectively. In another study by Marri and Ahmed, the prevalence of hepatitis B in Quetta was reported to be 11.0%.\textsuperscript{13}

The exact factors responsible for having majority of chronic HBV infections in the age group of 30 to 50 years is not well understood in this part of the world. Reuse of syringes, unscreened blood transfusions, tattoo marks with unsterilized needles, sexual transmission from husband to wife and vice versa, and illegitimate personal contacts are some of the means of spreading of infections, as explored in the interview with the subjects.

Kammerlander and Zimmermann have reported 80% of HBV subjects between 15 and 40 years while mean age of 38 years has been reported in a study conducted in Chile, Santiago.\textsuperscript{14,15} Sexual transmission, injection drug use and working in health care settings have been reported as the modes of HBV transmission in this age group.\textsuperscript{16,17}

Hepatitis B virus causes a lot of morbidity and mortality in Pakistan. Prevention is the only way to control the disease by avoiding risk factors and observing all the necessary precautions while handling the infected blood and body fluids. A mass screening of HBV may be done in endemic areas in Balochistan and all those who are HBsAg negative should be vaccinated. Hepatitis B vaccine is safe, effective and well tolerated.\textsuperscript{18}

WHO aims at controlling HBV worldwide to decrease the incidence of HBV-related chronic liver disease, cirrhosis, and hepatocellular carcinoma by integrating hepatitis B vaccination into routine infant (and possibly adolescent) immunization programs.\textsuperscript{1,5,10}

In 1991, the Global Advisory Group of EPI (Extended Programme on Immunization) set 1997 as the target for integrating the hepatitis B vaccination into national immunization programs worldwide. The group recommended strategies for implementation and delivery that vary according to epidemiology: advocating integration of the vaccine into immunization programs by 1995 in countries with HBV carrier prevalence of 8% or higher and setting 1997 as the target date for all other countries. WHO endorsed the recommendation in May 1992 and the World Health Assembly added a disease reduction target for hepatitis B in 1994, calling for an 80% decrease in new HBV child carriers by 2001.

Attaining global immunization coverage is a goal still unmet. Attempts at protecting the whole community by vaccinating only high-risk individuals have not been successful.\textsuperscript{19} Universal vaccination is necessary to control and possibly eradicate hepatitis B.

Screening of blood prior to transfusion and vaccination of the infants for HBV as part of the nationwide EPI campaign would help in limiting the spread of this infectious disease which has been one of the major causes of morbidity and mortality in this part of the world.

Commitment of public health resources to eliminate the spread of HBV requires recognition of the importance of hepatitis B, persistent efforts to ensure that populations are protected, and patience to achieve goals of disease reduction.\textsuperscript{10}

**REFERENCES**

1. Mahoney FJ, Kane M. Hepatitis B vaccine. In: Plotkin SA, Orenstein WA, editors. Vaccines. 3rd ed. Philadelphia: W.B. Saunders Company; 1999. p. 158-82.
2. Robinson WS. Hepatitis B virus and hepatitis D virus. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and Practice of Infectious Diseases. 4th ed. New York: Churchill Livingstone; 1995. p. 1406-39.
3. Mahoney FJ. Update on diagnosis, management and prevention of Hepatitis B virus infection. Clin Microbiol Rev 1999;12:351-66.
4. Kona MA. Worldwide epidemiology of Hepatitis B. Soz Praventivmed 1998;43:24-6, 98-100.
5. Hepatitis B virus: A comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination: Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep 1991;40:1-19.
6. Beasley RP, Hwang LY, Lin CC, Chein CS. Hepatocellular Carcinoma and Hepatitis B virus: A prospective study of 22707 men in Taiwan. Lancet 1981;2:1129-33.
7. Viral Hepatitis Prevention Board. Universal HB immunization by 1997: Where are we now? Fact Sheet VHPB/1998/2. Available from: http://hgnis.uia.ac.be/esoc/VHPB/vhfs2.html [last accessed on 2008].
8. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al. A one-year trial of lamivudine for chronic hepatitis B: Asia hepatitis lamivudine study group. N Engl J Med 1998;339:61-8.
9. Hollinger FB, Liang TJ. Hepatitis B Virus. In: Knipe DM, editors. Fields Virology. 4th ed. Philadelphia: Lippincott Williams and Wilkins; 2001. p. 2971-3036.
10. Van Damme P, Kane M, Meheus A. Integration of hepatitis B vaccination into national immunisation programmes. Br Med J 1997;314:1033-7.
11. Malik IA, Tariq WU. Viral hepatitis in Pakistan. Pak J Pathol 1993;4:15-8.
12. Ministry of Health, Annual Report, Director General Health, 2001-2002. Government of Pakistan, 2002.
13. Marri SM, Ahmed J. Prevalence of hepatitis B antigenemia in general population of Quetta, Balochistan. Biomedica 1997;13:51-2.
14. Kammerlander R, Zimmermann H. Epidemiology of hepatitis B in...
Sheik, et al.

15. Brah J, Hurtado C, Velasco M. Acute hepatitis by virus B in Chile: Clinical and developmental characteristics. Rev Med Chil 1990;118:264-8.
16. Balogun MA, Ramsay ME, Fairley CK, Collins M, Hetonstall J. Acute hepatitis B in England and Wales. Epidemiol Infect 1999;122:125-31.
17. Kane M. Epidemiology of hepatitis B in North America. Vaccine 1995;13:16-7.
18. Williams JR, Flowerdew AD. Uptake of immunization against hepatitis B among surgeons in Wessex Regional Health Authority.

BMJ 1990;301:154.
19. Viral Hepatitis Prevention Board. Antwerp VHPB Report. Editorial. Control of viral hepatitis in Europe. Viral Hepatitis. 1996;4. Available from: http://www.hgins.uia.ac.be/esoc/VHPB/vhv4n2.html [last accessed on 2010 Mar 25].

Source of Support: Nil, Conflict of Interest: None declared.

Author Help: Online submission of the manuscripts

Articles can be submitted online from http://www.journalonweb.com. For online submission, the articles should be prepared in two files (first page file and article file). Images should be submitted separately.

1) First Page File:
   Prepare the title page, covering letter, acknowledgement etc. using a word processor program. All information related to your identity should be included here. Use text/rtf/doc/pdf files. Do not zip the files.

2) Article File:
   The main text of the article, beginning with the Abstract to References (including tables) should be in this file. Do not include any information (such as acknowledgement, your names in page headers etc.) in this file. Use text/rtf/doc/pdf files. Do not zip the files. Limit the file size to 1 MB. Do not incorporate images in the file. If file size is large, graphs can be submitted separately as images, without their being incorporated in the article file. This will reduce the size of the file.

3) Images:
   Submit good quality color images. Each image should be less than 4 MB in size. The size of the image can be reduced by decreasing the actual height and width of the images (keep up to about 6 inches and up to about 1200 pixels) or by reducing the quality of image. JPEG is the most suitable file format. The image quality should be good enough to judge the scientific value of the image. For the purpose of printing, always retain a good quality, high resolution image. This high resolution image should be sent to the editorial office at the time of sending a revised article.

4) Legends:
   Legends for the figures/images should be included at the end of the article file.